SOLICITATION NOTICE
R -- Support of study activities of AsiaLymph study in Tianjin, China
- Notice Date
- 8/9/2012
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120171-MD
- Archive Date
- 9/7/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics DCEG plans to procure on a sole source basis with the Tianjin Medical University of Qixiangtai Road, Hexi District, Tianjin, 300060 to provide support of study activities of AsiaLymph study in Tianjin, China. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541990 and the business size standard is $14 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire Green Products or Services under this contract. The period of performance shall be twelve (12) months from date of award. The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm and extend these observations has become limited by the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium between key candidate genetic loci in Western populations. To optimize the ability to build on and clarify these findings, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. Thus, a hospital-based case-control study of lymphoma in Eastern Asia (i.e., AsiaLymph) to be enrolled over a three-year period shall be conducted. The major postulated risk factors for evaluation in this study are chemical exposures (i.e., organochlorines, trichloroethylene and benzene), genetic susceptibility and infectious agents. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping by two of the world's leading lymphoma pathologists, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph should serve to confirm and extend previous findings, and yield novel insights into the causes of lymphoma in both Asia and the West. The purpose is to provide support of study activities of AsiaLymph study in Tianjin. The NCI funded hospital-based case-control study of lymphoma (AsiaLymph) will be conducted in Taiwan, Hong Kong, and mainland China. The major postulated risk factors for evaluation in this study are chemical exposures such as organochlorines, trichloroethylene and benzene. To properly assess these exposures among lymphoma cases and controls, accurate and historical data assessing organochlorines, trichloroethylene and benzene levels in the various workplaces is critical. Tianjin Medical University is the premier lymphoma hospital in China, with extensive lymphoma cases and controls necessary for the AsiaLymph protocol. Further, researchers at Tianjin Medical University have the necessary historical data assessing various workplace chemical exposures. This data is comparable to similar data from the Hong Kong and Taiwan study centers, thus allowing for the necessary pooling and compatibility of data across all of AsiaLymph. Therefore, Tianjin Medical University is the only known hospital in Tianjin, China that can fulfill the requirements. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 23, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through SAM.gov. No collect calls will be accepted. Please reference solicitation number NCI-120171-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120171-MD/listing.html)
- Record
- SN02833274-W 20120811/120810001135-1e0483deff7954009a8e5e5bfbf91284 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |